Talis Biomedical Corp Stock Revenue
Talis Biomedical Corp fundamentals help investors to digest information that contributes to Talis Biomedical's financial success or failures. It also enables traders to predict the movement of Talis Pink Sheet. The fundamental analysis module provides a way to measure Talis Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Talis Biomedical pink sheet.
Talis |
Talis Biomedical Corp Company Revenue Analysis
Talis Biomedical's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Talis Biomedical Revenue | 412 K |
Most of Talis Biomedical's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Talis Biomedical Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Talis Biomedical Corp reported 412 K of revenue. This is 99.99% lower than that of the Health Care Equipment & Supplies sector and 99.98% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Talis Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Talis Biomedical's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Talis Biomedical could also be used in its relative valuation, which is a method of valuing Talis Biomedical by comparing valuation metrics of similar companies.Talis Biomedical is currently under evaluation in revenue category among its peers.
Talis Fundamentals
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (113.60) % | ||||
| Current Valuation | (38.24 M) | ||||
| Shares Outstanding | 1.82 M | ||||
| Shares Owned By Insiders | 8.30 % | ||||
| Shares Owned By Institutions | 52.15 % | ||||
| Number Of Shares Shorted | 17.96 K | ||||
| Price To Book | 0.06 X | ||||
| Price To Sales | 19.57 X | ||||
| Revenue | 412 K | ||||
| Gross Profit | (149.4 M) | ||||
| EBITDA | (60.7 M) | ||||
| Net Income | (62.01 M) | ||||
| Cash And Equivalents | 165.37 M | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 19.67 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 12.51 X | ||||
| Book Value Per Share | 26.68 X | ||||
| Cash Flow From Operations | (53.24 M) | ||||
| Short Ratio | 0.59 X | ||||
| Earnings Per Share | (28.02) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 99 | ||||
| Beta | 1.62 | ||||
| Market Capitalization | 7.98 M | ||||
| Total Asset | 98.34 M | ||||
| Retained Earnings | (539.96 M) | ||||
| Working Capital | 68.91 M | ||||
| Net Asset | 98.34 M |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stocks Directory Find actively traded stocks across global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |